DGAP-News: CatalYm GmbH: CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
The poster
A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER) , Abstract TPS2658
, will present CatalYm s first-in-human, two-part, open-label phase 1 clinical trial of CTL-002, a neutralizing antibody targeting GDF-15. GDF-15 is a factor that is secreted by several major tumor entities and interferes with effector T cell recruitment. In the GDFATHER-trial, patients with advanced-stage, solid tumors who have not responded or stopped responding to anti-PD-1/PD-L1 therapy are treated with CTL-002 as monotherapy and followed by combination with an anti-PD-1 antibody. The first patient was enrolled in December 2020.
Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial
Many vaccines are being trialed against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the enveloped virus causing the current coronavirus disease 2019 (COVID-19) pandemic.
Newer and more effective vaccines are urgently required due to the rapid emergence of highly transmissible and perhaps more virulent virus lineages that often confer immune escape. Along with this observation, it is pertinent that global immunization will take months, if not years, to complete.
During this time, hundreds of thousands of severe COVID-19 cases will need to be treated, making new vaccines a priority to prevent the overwhelming of health services.
In this article, we investigate three of the latest developments in COVID-19 therapeutics that are delivered intranasally.
With the rapid development of COVID-19 treatments and vaccines, one avenue of investigation for researchers aiming to enhance their therapeutics is exploring different forms of drug delivery, including intranasal sprays. Here, we look at three recent developments in COVID-19 intranasal drug delivery:
A COVID-19 vaccine
Codagenix and the Serum Institute of India (SII) received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial of COVI-VAC, a single-dose intranasal, live attenuated vaccine against COVID-19.